Intracavernosal injection, commonly abbreviated ICI, is the direct delivery of a vasodilating drug into the spongy tissue of the penis to produce an erection. Urologists use it both as a treatment for erectile dysfunction and as a diagnostic tool, and it has been around since the early 1980s. Despite the arrival of oral medications like sildenafil in the late 1990s, ICI remains one of the most effective options for men who do not respond to pills, with success rates that consistently outperform other non-surgical therapies.
How ICI Works
The penis contains two cylindrical chambers called the corpora cavernosa, which fill with blood during arousal. In ICI, a small needle delivers a vasodilator directly into one of these chambers. The drug relaxes the smooth muscle lining the chamber walls and widens the cavernous arteries, allowing blood to rush in and produce rigidity.1PubMed Central. Intracavernous Injection Therapy as Second-Line Treatment for ED After Radical Prostatectomy: A Literature Review Because the medication bypasses the brain-to-nerve-to-blood-vessel signaling chain that oral drugs depend on, ICI can work even when those pathways are damaged or impaired.2PubMed. Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction
The erection typically develops within five to fifteen minutes of the injection and lasts long enough for intercourse, though the exact duration depends on the drug and dose. Because the medication acts locally, systemic side effects like dizziness or blood pressure drops are rare, unlike some alternatives that deliver drugs through the bloodstream.
The Medications Used
Several vasodilators can be injected, alone or in combination. The most widely studied single agent is alprostadil, a synthetic form of prostaglandin E1. In a dose-response study of nearly 300 men, all doses of alprostadil outperformed placebo, with response rates climbing as the dose increased. In a separate six-month trial of 683 men who self-injected at home, participants reported being able to have sexual activity after about 94 percent of injections, and both the men and their partners rated the experience as satisfactory roughly 87 percent of the time.3PubMed. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction
Alprostadil is not the only option. Papaverine, an older smooth-muscle relaxant, was actually the first drug used for ICI back in 1982. Phentolamine, which blocks certain nerve receptors that keep blood vessels constricted, is often combined with papaverine or alprostadil. The most common combination today is “trimix,” a mixture of papaverine, phentolamine, and prostaglandin E1. A newer formulation pairs aviptadil (a vasoactive intestinal polypeptide) with phentolamine.4PubMed. A comprehensive history of injection therapy for erectile dysfunction, 1982-2023 Each combination has a slightly different side-effect profile, and urologists often switch between them depending on how a patient responds.
In one study of men with refractory erectile dysfunction who tried aviptadil plus phentolamine, about 59 percent found it effective overall. Among men who had only partially responded to prior treatment, the success rate reached 76 percent.5PubMed. Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction This kind of drug-switching flexibility is one of the reasons ICI remains useful even decades after its introduction.
ICI as a Diagnostic Tool
Beyond treatment, urologists frequently use ICI as part of a diagnostic workup. When a man has erectile dysfunction and the underlying cause is unclear, injecting alprostadil into the penis and then performing a Doppler ultrasound lets the clinician watch blood flow in real time. The ultrasound measures how fast blood enters through the arteries and how quickly (or slowly) it leaks back out through the veins.
In a large analysis of over 9,100 patients who underwent this procedure, researchers used those flow measurements to sort men into categories: those with arterial problems, those with venous problems, and those with no vascular cause at all.6PubMed Central. Color Doppler ultrasound results of erectile dysfunction patients after an intracavernosal injection of prostaglandin E1: an analysis of 9,109 cases The typical protocol uses 10 micrograms of alprostadil. Arterial erectile dysfunction is flagged when peak blood-flow speeds fall below a certain threshold, with more severe cases showing even lower values.7PubMed. The penile duplex ultrasound: How and when to perform it? This test helps determine whether a man needs medication, surgery, or a different approach entirely, so the diagnostic use of ICI often precedes any treatment decision.
How the Injection Is Performed
The idea of injecting the penis understandably makes many men anxious, but the needle is very fine, similar to an insulin syringe. The injection goes into the side of the shaft, roughly at the midpoint, avoiding visible veins and the urethra on the underside. Patients are typically trained to inject with the dominant hand into the same side of the penis.8Sexual Medicine. Retained needles during intracavernosal self-injection for erectile dysfunction treatment: a case report and systematic literature review During the first office visit, a urologist or nurse demonstrates the technique, walks through each step, and supervises the patient’s first self-injection. The clinician also adjusts the dose during these early visits, starting low and increasing gradually until the erection is firm enough for intercourse but not lasting too long.
Alternating sides with each injection is standard advice. This reduces repeated trauma to the same tissue and lowers the risk of scar buildup over time. Most men report that the discomfort of the injection itself is minor once they get used to it, though some find the psychological hurdle harder to overcome than the physical one.
How ICI Compares to Oral Medications and Other Alternatives
Oral phosphodiesterase type 5 inhibitors (PDE5 inhibitors) like sildenafil, tadalafil, and vardenafil are the first-line treatment for erectile dysfunction. They are easier to take and less invasive. But for men whose ED does not respond to pills, ICI is generally the next step. Past meta-analyses have found a pooled success rate of about 90 percent for ICI in achieving a satisfactory erection, and head-to-head comparisons within the same group of patients have shown ICI producing better results than sildenafil.9Spinal Cord Injury Research Evidence. Intracavernosal Injections (ICI) Utilizing Penile Medications
Another alternative is MUSE (medicated urethral system for erection), which delivers alprostadil through a tiny pellet inserted into the urethra rather than via needle. It sounds more appealing to many patients, but its effectiveness is notably lower. In a comparative study of 103 men, intracavernosal alprostadil achieved a 70 percent overall response rate compared to 43 percent for MUSE. Fully rigid erections occurred in 48 percent of ICI users versus just 10 percent with MUSE. MUSE also caused more penile pain and occasional systemic effects like dizziness and drops in blood pressure.10International Journal of Impotence Research. Transurethral Alprostadil with MUSE (medicated urethral system for erection) vs intracavernous Alprostadil—a comparative study in 103 patients with erectile dysfunction A randomized study confirmed these patterns: about 90 percent of the ICI group achieved a good erection during office dosing versus 60 percent of the MUSE group, and intercourse rates at home followed a similar gap.11PubMed. Intracavernosal versus intraurethral alprostadil: a prospective randomized study Still, MUSE remains an option for men who refuse needles altogether.
Side Effects and Risks
The side effects of ICI tend to be local rather than systemic, which is part of its appeal. But they are real and worth understanding before starting treatment.
- Penile pain: A mild ache or burning at the injection site is common, especially with alprostadil. In men using ICI after radical prostatectomy, average pain scores were around 3 out of 10 at six months and dropped to about 2.5 out of 10 by twelve months.12PubMed. Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy The pain tends to correlate with the drug’s concentration rather than the needle itself.
- Priapism: This is an erection lasting four hours or longer that will not resolve on its own. It is a medical emergency because prolonged engorgement without fresh blood flow can permanently damage penile tissue. The risk is highest with papaverine-based formulations and tends to occur early in treatment before the dose is properly calibrated.13PubMed Central. Management of priapism: an update for clinicians In a penile rehabilitation program after prostate surgery, priapism occurred in fewer than 2 percent of patients overall.14The Journal of Sexual Medicine. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy
- Penile fibrosis and Peyronie’s-like changes: Repeated injections can cause scar tissue to form in the penis, sometimes leading to curvature or hard plaques similar to Peyronie’s disease. Case reports have documented this with prostaglandin E1.15PubMed. Peyronie’s-like plaque after penile injection of prostaglandin E1 In a survey of urologists, about 68 percent said they counsel patients that ICI can cause Peyronie’s disease, and 57 percent believed it causes corporal fibrosis.16The Journal of Sexual Medicine. Expert Opinions on Intracavernosal Injections and Their Link to Peyronie’s Disease and Penile Fibrosis Alternating injection sites and using proper technique help reduce the risk.
Men who experience an erection lasting more than two to three hours should seek medical attention. The standard emergency treatment involves aspirating blood from the penis with a needle and injecting a sympathomimetic drug (the opposite kind of drug to what caused the erection) to constrict the blood vessels.
Why Many Men Stop Using ICI
Despite strong efficacy numbers, long-term adherence to self-injection therapy is a well-known problem. In one study tracking 144 patients, about a quarter never started home therapy after their office training. Among those who did start, 40 percent eventually dropped out after an average of about seven months. Only 36 percent were still using ICI at the time of follow-up. The reasons for stopping were revealing: dissatisfaction with the quality of the experience, cost, feeling that injections were “unnatural,” and inadequate erections all ranked among the top causes. Interestingly, some men dropped out because their spontaneous erections returned.17PubMed. Reasons of dropout from short- and long-term self-injection therapy for impotence
A separate long-term comparison found that at the time of follow-up, only 41 percent of patients were still using ICI, and the average duration of use was 37 months, roughly half the duration of men who had opted for a penile prosthesis. The most common reasons for quitting were inadequate erections, lack of spontaneity, and side effects.18The Journal of Urology. Comparison of Long-Term Outcomes of Penile Prostheses and Intracavernosal Injection Therapy Another study found that the men who continued treatment long-term were distinguished not so much by fewer side effects as by higher motivation, greater satisfaction with the results, a perception that the injections required minimal effort, and an improvement in self-esteem.19PubMed. Reasons for discontinuing intracavernous injection therapy with prostaglandin E1 (alprostadil) In other words, the psychological fit matters as much as the physical results.
Among men who discontinued ICI, more than half remained sexually active by switching to other therapies or, in some cases, needing no treatment at all.20PubMed. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy So dropping out of ICI does not necessarily mean giving up on sexual activity.
ICI After Radical Prostatectomy
One of the most common clinical scenarios for ICI is penile rehabilitation after prostate cancer surgery. Nerve-sparing radical prostatectomy can damage the nerves responsible for erections, and even when the surgeon preserves them, months or years may pass before function recovers. The rationale for early penile rehabilitation is that regular oxygenation of the erectile tissue, achieved by producing periodic erections, may prevent the structural damage that occurs when the penis goes without blood flow for extended periods.21PubMed Central. Penile rehabilitation after radical prostatectomy: does it work?
In practice, many urologists start patients on daily low-dose oral PDE5 inhibitors after surgery and add ICI for the actual erections. A program tracking men who combined daily tadalafil or sildenafil with trimix injections found that priapism was uncommon, occurring in fewer than 2 percent of users, though men on tadalafil had a somewhat higher rate of prolonged erections, especially during the first few injections at home while the dose was being fine-tuned.14The Journal of Sexual Medicine. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy The evidence that rehabilitation programs lead to better long-term erection recovery remains mixed, but the basic science supporting early intervention is strong enough that most major centers offer it as an option.
ICI for Spinal Cord Injury
Men with spinal cord injuries often have erectile dysfunction caused by disrupted nerve signals rather than vascular disease, which makes ICI especially well suited. A systematic review and meta-analysis of these patients found that ICI produced successful erections in about 88 percent of cases. The combination of papaverine and phentolamine had the highest success rate at 93 percent, papaverine alone achieved 91 percent, and alprostadil monotherapy was somewhat lower at 80 percent. The researchers could not identify any specific factor, including the level of injury, completeness of injury, or patient age, that reliably predicted who would respond.22PubMed. Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis For this population, ICI is often first-line rather than second-line treatment, because oral medications depend on intact nerve pathways that may be absent.
How Partners Experience ICI
The impact of ICI on the couple, not just the patient, is an underappreciated part of the story. Research on men using self-injection therapy has shown improvements in erection quality, intercourse frequency, and sexual satisfaction for patients. Partners reported increases in intercourse frequency, arousal during sex, and satisfaction as well. The men also showed reduced general psychiatric symptoms and improved self-esteem and relationship satisfaction. Partners, however, did not show the same psychological gains.23PubMed. Intracavernosal injection in the treatment of impotence: a prospective study of sexual, psychological, and marital functioning
Satisfaction with ICI appears tied to specific, identifiable factors. On multivariate analysis, men who were older, had younger partners, saw a meaningful jump in erectile function scores, and achieved a fully rigid erection were more likely to report high satisfaction.24PubMed. Satisfaction profiles in men using intracavernosal injection therapy Among women partnered with men using ICI after prostate surgery, overall sexual quality of life was low, but it correlated strongly with how well the male partner responded to the injections. Injection-related pain in the man, his increasing age, and urinary problems from surgery all negatively affected the woman’s sexual experience.25PubMed. Sexual quality of life in women partnered with men using intracavernous alprostadil injections after radical prostatectomy These findings suggest that managing side effects like pain is not just about the patient’s comfort but about preserving the sexual relationship.
A Brief History of ICI
Before oral medications existed, ICI was the primary non-surgical option for erectile dysfunction. The French surgeon Ronald Virag reported using papaverine injections in 1982. A year later, the British physiologist Giles Brindley famously demonstrated the technique at an American Urological Association meeting by injecting himself onstage and displaying the result to the audience, a moment that shocked the field into taking the approach seriously. Over the next few years, phentolamine was added to papaverine, and prostaglandin E1 arrived in 1986. The combination drugs followed, and trimix became the standard multi-agent formulation.4PubMed. A comprehensive history of injection therapy for erectile dysfunction, 1982-2023
When sildenafil was approved in 1998, many predicted that injection therapy would disappear. That has not happened, partly because a substantial minority of men do not respond to oral drugs and partly because ICI remains the most effective non-surgical option available. The development of newer agents like aviptadil/phentolamine suggests the field is still evolving rather than winding down. For men willing to get past the initial discomfort of a needle, ICI continues to occupy a unique and durable niche in the treatment of erectile dysfunction.